WASHINGTON — The Democratic-controlled House passed an $8.3 billion measure Wednesday to battle the coronavirus outbreak that’s spreading rapidly and threatening a major shock to the economy and disruptions to everyday life in the U.S.
The swift and sweeping bipartisan vote was a relative rarity in a polarized Washington and came just nine days after the president outlined a $2.5 billion plan that both Trump’s GOP allies and Democratic critics said was insufficient.
The 415-2 vote came after House Speaker Nancy Pelosi beat a tactical retreat on vaccine price guarantees and followed a debate that lasted only a few minutes.
“The government’s greatest responsibility is to keep Americans safe,” said House Appropriations Committee Chairwoman Nita Lowey, D-N.Y. “This emergency supplemental addresses the coronavirus and takes critical steps to protect the American people from this deadly and expanding outbreak.”
The Senate is likely to pass the measure today and send it to the White House for Trump’s signature. The legislation came together in little more than a week — and more than triples Trump’s request — sped along by fears of the outbreak’s growing threat.
Trump is sure to sign the measure, which has the blessing of top Republicans like Senate Majority Leader Mitch McConnell, R-Ky., and top House Republican Kevin McCarthy of California.
“This moment calls for collaboration and unity,” McConnell said. “It’s time to give our public health experts and healthcare professionals the surge resources they need at this challenging time.”
The agreement came together after Pelosi, D-Calif., dropped a demand, opposed by Republicans and the drug industry, to guarantee that any vaccines and drug treatments developed with government-backed research — but manufactured by drug companies — be offered at “affordable” prices. Pelosi opted to avoid a confrontation that could have delayed the legislation’s path through Congress.
Instead, more than $3 billion would be dedicated to research and development on vaccines, medicines for treatment, and diagnostic tests, including $300 million for the government to purchase such drugs from manufacturers at “fair and reasonable” prices to distribute them to those who need it — which is the standard applied in earlier crises like the 2009 H1N1 flu outbreak.
It also would provide more than $2 billion to help federal, state and local governments prepare for and respond to the coronavirus threat, including $300 million for the Centers for Disease Control and Prevention’s rapid response fund. Another $1.3 billion would be used to help fight the virus overseas.
